CompanyKURANasdaqSan Diego, CA

Kura Oncology, Inc.

Kura Oncology develops small molecule drugs targeting cancer signaling pathways for hematologic malignancies and solid tumors.

SEC EDGAR ClinicalTrials.gov kuraoncology.com

10-QSep 18Latest SEC filing, period to Jun 30

Sep 8Latest story

September 2026

Kura Oncology names Jennifer Fulk as chief financial officer

Sep 8PeopleKura Oncology, Inc.

August 2026

Kura Oncology posts $9.1 million in KOMZIFTI revenue in second quarter of 2026

Aug 12Quarterly updateKura Oncology, Inc.ziftomenib

July 2026

Kura Oncology updates severance terms for CEO and two other executives

Jul 29PeopleKura Oncology, Inc.